Venture Capital

Family safety app Life360 acquires ad-tech firm Nativo, using its vast location data to build an ad empire. Can it balance profit with user privacy?

At CES 2026, Ubicept's new toolkit promises to let AI see clearly in the dark and at high speed, ushering in a new era for robotics and autonomous cars.

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

With deep institutional and private sector tech experience, new CEO Andrew Bercich is tasked with guiding the U.S. workforce system through a pivotal era.

With promising 3-year vision data and a manufacturing breakthrough, Lineage is pioneering 'off-the-shelf' cell therapies for blindness, diabetes, and more.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

A premium meal service enters the D.C. market not with ads, but with community aid and a rare, profitable business model that defies industry trends.

A new partnership aims to unlock the potential of a next-gen obesity drug by pairing it with advanced delivery tech to overcome historical hurdles.

With a key drug decision looming and a refocused strategy, Rocket Pharmaceuticals faces a critical audience at the J.P. Morgan Healthcare Conference.

Sanofi is investing up to $2.56 billion in Earendil Labs' AI platform to discover next-gen bispecific antibodies for complex autoimmune diseases.

With key trials in brain and prostate cancer, Curasight heads to a top investor conference to showcase its dual-action theranostic technology.

Abingworth elevates Bali Muralidhar and hires Travis Wilson, signaling a major push into clinical co-development and buyouts under Carlyle's wing.

Civinity now wholly owns workforce platform Valandinis in a €1.26M deal, signaling a major shift towards vertical integration in the Baltic construction market.

Facing a 79% stock plunge, automotive tech firm MKDWELL repurchases shares worth 77% of its market cap in a bold display of confidence.

Solmate Infrastructure appoints financial heavyweight Erez Simha to its board, bolstering its ambitious plan to build a Solana hub in Abu Dhabi.